{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=low+intensity+radiation+therapy", "query": { "intervention": "low intensity radiation therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 105, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=low+intensity+radiation+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T00:07:17.217Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04339777", "title": "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorders", "Autoimmune Lymphoproliferative", "Immune System Diseases", "Common Variable Immunodeficiency", "Primary T-cell Immunodeficiency Disorders" ], "interventions": [ { "name": "Busulfan test dose", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total body Irradiation", "type": "RADIATION" }, { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Tacrolimus (Tacro)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Cyclophosphamide (Cytoxan)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "4 Years to 69 Years" }, "enrollment_count": 66, "start_date": "2020-09-22", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04339777" }, { "nct_id": "NCT01804634", "title": "Reduced Intensity Haploidentical BMT for High Risk Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory and/or Relapsed Metastatic Solid Tumors" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "low dose total body irradiation", "type": "RADIATION" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "50 Years", "sex": "ALL", "summary": "1 Year to 50 Years" }, "enrollment_count": 60, "start_date": "2013-03-27", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 3, "location_summary": "Baltimore, Maryland • The Bronx, New York • Valhalla, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "The Bronx", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01804634" }, { "nct_id": "NCT04900623", "title": "Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV-Associated Oropharyngeal Squamous Cell Carcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage", "HPV-Related Squamous Cell Carcinoma", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage", "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage" ], "interventions": [ { "name": "NavDx HPV ctDNA Testing", "type": "DEVICE" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Chemotherapy drug", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "RADIATION", "DRUG" ], "sponsor": "Jonathan Schoenfeld, MD, MPH", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 145, "start_date": "2021-07-02", "completion_date": "2032-06-01", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900623" }, { "nct_id": "NCT05388773", "title": "Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharynx Cancer" ], "interventions": [ { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "OTHER" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION", "DRUG" ], "sponsor": "Heath Skinner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2022-07-20", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05388773" }, { "nct_id": "NCT00002634", "title": "Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "monoclonal antibody 3F8", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "perfosfamide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "low-LET cobalt-60 gamma ray therapy", "type": "RADIATION" }, { "name": "low-LET photon therapy", "type": "RADIATION" }, { "name": "radioisotope therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 45, "start_date": "1995-02", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2013-07-03", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002634" }, { "nct_id": "NCT01529827", "title": "Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Aplastic Anemia", "Burkitt Lymphoma", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Grade III Lymphomatoid Granulomatosis", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Congenital Amegakaryocytic Thrombocytopenia", "Diamond-Blackfan Anemia", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Paroxysmal Nocturnal Hemoglobinuria", "Peripheral T-cell Lymphoma", "Polycythemia Vera", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Secondary Myelofibrosis", "Severe Combined Immunodeficiency", "Severe Congenital Neutropenia", "Shwachman-Diamond Syndrome", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Waldenstrom Macroglobulinemia", "Wiskott-Aldrich Syndrome" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "3 Years to 75 Years" }, "enrollment_count": 94, "start_date": "2012-02-28", "completion_date": "2019-08-29", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01529827" }, { "nct_id": "NCT03174275", "title": "Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell", "Oral Cancer", "Oropharynx Cancer", "Larynx Cancer", "Lip Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgical resection", "type": "PROCEDURE" }, { "name": "IMRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-12-19", "completion_date": "2027-02-02", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03174275" }, { "nct_id": "NCT03799445", "title": "Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma", "Oropharyngeal Basaloid Carcinoma", "Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Posterior Tongue Squamous Cell Carcinoma", "Soft Palate Squamous Cell Carcinoma", "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Tonsillar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-07-25", "completion_date": "2026-04-14", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03799445" }, { "nct_id": "NCT00054353", "title": "Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2002-10", "completion_date": "2012-10-14", "has_results": true, "last_update_posted_date": "2017-10-16", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054353" }, { "nct_id": "NCT04882280", "title": "Dose-dependent Impact of Daytime Lighting on Evening Responses to Light", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sleep" ], "interventions": [ { "name": "Light", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Palo Alto Veterans Institute for Research", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2022-07", "completion_date": "2024-07", "has_results": false, "last_update_posted_date": "2022-03-17", "last_synced_at": "2026-09-26T00:07:17.217Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04882280" } ] }